Radiology, Vol 200, 489-496, Copyright © 1996 by Radiological Society of North America

ARTICLES

Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging

J Kurhanewicz, DB Vigneron, H Hricak, F Parivar, SJ Nelson, K Shinohara and PR Carroll
Department of Radiology, University of California, San Francisco 94143- 0738, USA.

PURPOSE: To determine, in patients with prostate cancer treated with cryosurgery, whether levels of choline and citrate measured at magnetic resonance (MR) spectroscopy can help discriminate regions of residual tumor from other prostatic tissues and necrosis. MATERIALS AND METHODS: Combined MR imaging and three-dimensional proton spectroscopic imaging were performed in 25 patients (mean age, 69 years) with prostate cancer who underwent cryosurgery. Volume imaging and spectroscopic data were analytically corrected for the reception profile of the endorectal and pelvic phased-array coils. Spectral data were aligned with the MR imaging data and compared with serum prostate-specific antigen levels and biopsy results. RESULTS: Histologically confirmed necrotic tissue (432 voxels) did not demonstrate any observable choline or citrate. The (choline + creatine)/ citrate values in regions of histologically confirmed benign prostatic hyperplasia (0.61 +/- 0.21 [standard deviation], 52 voxels) and cancer (2.4 +/- 1.0, 65 voxels) after cryosurgery were not statistically significantly different from those before therapy but were statistically significantly different from the ratio in necrotic tissue and from each other. The (choline + creatine)/citrate images threshold and overlaid in color on T2-weighted images yielded an estimate of the spatial extent of prostate cancer and benign prostatic hyperplasia. CONCLUSION: Volume MR imaging with MR spectroscopic imaging provided a noninvasive assessment of the presence and location of residual cancer after unsuccessful therapy and helped identify successful cryosurgery in patients who still had an elevated prostate-specific antigen level.

This article has been cited by other articles:

				F. Hyodo, K.-i. Matsumoto, A. Matsumoto, J. B. Mitchell, and M. C. Krishna Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents. Cancer Res., October 15, 2006; 66(20): 9921 - 9928. [Abstract] [Full Text] [PDF]

				F. V. Coakley, H. S. Teh, A. Qayyum, M. G. Swanson, Y. Lu, M. Roach III, B. Pickett, K. Shinohara, D. B. Vigneron, and J. Kurhanewicz Endorectal MR Imaging and MR Spectroscopic Imaging for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy: Preliminary Experience Radiology, November 1, 2004; 233(2): 441 - 448. [Abstract] [Full Text] [PDF]

				K. L. Zakian, S. Eberhardt, H. Hricak, A. Shukla-Dave, S. Kleinman, M. Muruganandham, K. Sircar, M. W. Kattan, V. E. Reuter, P. T. Scardino, et al. Transition Zone Prostate Cancer: Metabolic Characteristics at H MR Spectroscopic Imaging--Initial Results Radiology, October 1, 2003; 229(1): 241 - 247. [Abstract] [Full Text] [PDF]

				P. Swindle, S. McCredie, P. Russell, U. Himmelreich, M. Khadra, C. Lean, and C. Mountford Pathologic Characterization of Human Prostate Tissue with Proton MR Spectroscopy Radiology, July 1, 2003; 228(1): 144 - 151. [Abstract] [Full Text] [PDF]

				A J Schwarz, N R Maisey, D J Collins, D Cunningham, R Huddart, and M O Leach Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours Br. J. Radiol., December 1, 2002; 75(900): 959 - 966. [Abstract] [Full Text] [PDF]

				J. Kotzerke, J. E. Gschwend, and B. Neumaier PET for Prostate Cancer Imaging: Still a Quandary or the Ultimate Solution? J. Nucl. Med., February 1, 2002; 43(2): 200 - 202. [Full Text] [PDF]

				E. Ackerstaff, B. R. Pflug, J. B. Nelson, and Z. M. Bhujwalla Detection of Increased Choline Compounds with Proton Nuclear Magnetic Resonance Spectroscopy Subsequent to Malignant Transformation of Human Prostatic Epithelial Cells Cancer Res., May 1, 2001; 61(9): 3599 - 3603. [Abstract] [Full Text]

				J. R. Thornbury, D. K. Ornstein, P. L. Choyke, C. P. Langlotz, and J. C. Weinreb Prostate Cancer: What Is the Future Role for Imaging? Am. J. Roentgenol., January 1, 2001; 176(1): 17 - 22. [Full Text]

				M. van der Graaf, H. J. van den Boogert, G. J. Jager, J. O. Barentsz, and A. Heerschap Human Prostate: Multisection Proton MR Spectroscopic Imaging with a Single Spin-Echo Sequence-Preliminary Experience Radiology, December 1, 1999; 213(3): 919 - 925. [Abstract] [Full Text]

				J. Scheidler, H. Hricak, D. B. Vigneron, K. K. Yu, D. L. Sokolov, L. R. Huang, C. J. Zaloudek, S. J. Nelson, P. R. Carroll, and J. Kurhanewicz Prostate Cancer: Localization with Three-dimensional Proton MR Spectroscopic Imaging-Clinicopathologic Study Radiology, November 1, 1999; 213(2): 473 - 480. [Abstract] [Full Text]

				K. K. Yu, J. Scheidler, H. Hricak, D. B. Vigneron, C. J. Zaloudek, R. G. Males, S. J. Nelson, P. R. Carroll, and J. Kurhanewicz Prostate Cancer: Prediction of Extracapsular Extension with Endorectal MR Imaging and Three-dimensional Proton MR Spectroscopic Imaging Radiology, November 1, 1999; 213(2): 481 - 488. [Abstract] [Full Text]